239 related articles for article (PubMed ID: 28712935)
1. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation.
Introna M; Lussana F; Algarotti A; Gotti E; Valgardsdottir R; Micò C; Grassi A; Pavoni C; Ferrari ML; Delaini F; Todisco E; Cavattoni I; Deola S; Biagi E; Balduzzi A; Rovelli A; Parma M; Napolitano S; Sgroi G; Marrocco E; Perseghin P; Belotti D; Cabiati B; Gaipa G; Golay J; Biondi A; Rambaldi A
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2070-2078. PubMed ID: 28712935
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
[TBL] [Abstract][Full Text] [Related]
3. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
Merker M; Salzmann-Manrique E; Katzki V; Huenecke S; Bremm M; Bakhtiar S; Willasch A; Jarisch A; Soerensen J; Schulz A; Meisel R; Bug G; Bonig H; Klingebiel T; Bader P; Rettinger E
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1281-1292. PubMed ID: 30878607
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
5. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
6. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
7. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
9. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.
Takami A; Okumura H; Yamazaki H; Kami M; Kim SW; Asakura H; Endo T; Nishio M; Minauchi K; Kumano K; Sugimori N; Mori S; Takemoto Y; Shimadoi S; Ozaki J; Takaue Y; Nakao S
Int J Hematol; 2005 Dec; 82(5):449-55. PubMed ID: 16533751
[TBL] [Abstract][Full Text] [Related]
10. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD.
He F; Warlick E; Miller JS; MacMillan M; Verneris MR; Cao Q; Weisdorf D
Bone Marrow Transplant; 2016 Aug; 51(8):1107-12. PubMed ID: 27064686
[TBL] [Abstract][Full Text] [Related]
11. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
[TBL] [Abstract][Full Text] [Related]
12. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
[TBL] [Abstract][Full Text] [Related]
14. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
15. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.
Sairafi D; Remberger M; Uhlin M; Ljungman P; Ringdén O; Mattsson J
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1728-37. PubMed ID: 20542125
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].
Slesarchuk OA; Babenko EV; Semenova EV; Bondarenko SN; Éstrina MA; Morozova EV; Paina OV; Vavilov VN; Smirnov BI; Zubarovskaia LS; Afanas'ev BV
Ter Arkh; 2013; 85(7):26-33. PubMed ID: 24137944
[TBL] [Abstract][Full Text] [Related]
17. Donor Lymphocyte Infusion for Relapsed Acute Leukemia or Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation: A Single-Institute Retrospective Analysis.
Ogasawara M; Nozu R; Miki K; Sugimura S; Kojima K; Hidaka D; Ogasawara R; Okada K; Sugita J; Kobayashi N; Imamura M; Ota S
Intern Med; 2024 Jan; 63(2):197-205. PubMed ID: 37225485
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation.
Wang T; Gao L; Hu X; Liu B; Chen J; Zhang W; Wang J; Yu X; Feng D; Chang AE; Max W; Tang G; Li Q; Yang J
J Immunother; 2019 Apr; 42(3):81-88. PubMed ID: 30829725
[TBL] [Abstract][Full Text] [Related]
19. [Prophylactic G-CSF mobilized donor lymphocytes infusion after non-myeloablative stem cell transplantation prevents relapse in patients with high-risk leukemia].
Zhao HX; Sun WJ; Li J; Qiao JX; Huang YJ; Hu HL; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):922-5. PubMed ID: 24294845
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
